Literature DB >> 3266378

Defective cell mediated immunity in sarcoidosis: effect of interleukin-2.

D J Lyons1, L Gao, E B Mitchell, D N Mitchell.   

Abstract

Interleukin-2 has been reported to enhance the immune response in diseases characterised by defective cell mediated immunity. The effect of exogenous recombinant interleukin-2 was studied on the proliferative and cytotoxic responses of peripheral blood mononuclear cells from 39 patients with sarcoidosis and 14 healthy control subjects. The proliferative response to purified protein derivative was smaller in patients than in control subjects (p less than 0.001) whereas the response to 80 U interleukin-2 alone and to purified protein derivative and interleukin-2 did not differ significantly between the two groups. In addition, in eight patients but no control subjects tritiated thymidine incorporation induced by the combination of purified protein derivative and interleukin-2 was more than twice the sum of that induced by purified protein derivative and interleukin separately. Cytotoxic activity occurring spontaneously and induced by purified protein derivative and interleukin-2 in blood mononuclear cells was significantly less for patients with sarcoidosis than for control subjects (p less than 0.05 spontaneous, less than 0.001 purified protein derivative induced, less than 0.02 interleukin induced). Synergism between antigen and interleukin did not occur with respect to the cytotoxic response in either patients or controls. Defective interleukin-2 production may contribute to, but does not entirely explain, the functional abnormalities of peripheral blood lymphocytes from patients with sarcoidosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3266378      PMCID: PMC461612          DOI: 10.1136/thx.43.12.992

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  20 in total

1.  Prevalence and specificity of the enhancing effect of three types of interleukin 2 on T cell responsiveness in 97 lepromatous leprosy patients of mixed ethnic origin.

Authors:  S Barnass; J Mace; J Steele; P Torres; B Gervasoni; R Ravioli; J Terencio; G A Rook; M F Waters
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

2.  Phenotypical and functional analysis of natural killer cells in sarcoidosis.

Authors:  C Agostini; L Trentin; R Zambello; M Luca; A Cipriani; G Pizzolo; G Semenzato
Journal:  Clin Immunol Immunopathol       Date:  1985-11

3.  Defective interleukin 2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin 2.

Authors:  K Welte; N Ciobanu; M A Moore; S Gulati; R J O'Reilly; R Mertelsmann
Journal:  Blood       Date:  1984-08       Impact factor: 22.113

4.  Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis.

Authors:  P Emery; G S Panayi; A M Nouri
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

5.  Enhanced alveolar macrophage-mediated antigen-induced T-lymphocyte proliferation in sarcoidosis.

Authors:  A Venet; A J Hance; C Saltini; B W Robinson; R G Crystal
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

6.  Impaired production of interleukin-2 in peripheral blood of patients with sarcoidosis.

Authors:  C Agostini; G Semenzato; R Zambello; L Trentin; M Luca; A Cipriani; A Tommasini; C Benettollo; G Gasparotto
Journal:  Boll Ist Sieroter Milan       Date:  1985

7.  Gamma interferon is spontaneously released by alveolar macrophages and lung T lymphocytes in patients with pulmonary sarcoidosis.

Authors:  B W Robinson; T L McLemore; R G Crystal
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

8.  Lymphokine-activated killer cell activity in rheumatoid arthritis.

Authors:  M Jíra; M Malkovský; A M Denman; B Loveland; D Lyons; A G Dalgleish; A D Webster
Journal:  Clin Exp Immunol       Date:  1987-06       Impact factor: 4.330

9.  Interleukin 2 regulates the expression of Tac antigen on peripheral blood T lymphocytes.

Authors:  K Welte; M Andreeff; E Platzer; K Holloway; B Y Rubin; M A Moore; R Mertelsmann
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

10.  The sarcoidosis-lymphoma syndrome.

Authors:  H Brincker
Journal:  Br J Cancer       Date:  1986-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.